- AU$53.62m
- AU$52.22m
- AU$17.13m
- 53
- 27
- 79
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.15 | ||
| Price to Tang. Book | 11.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.77% | ||
| Return on Equity | -68.36% | ||
| Operating Margin | -88.18% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 16.31 | 12.82 | 13.63 | 13.41 | 17.13 | 22.45 | 31 | -26.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nova Eye Medical Limited is an Australia-based medical technology company. The Company’s principal activities include the design, development, manufacture, marketing, sale, and distribution of surgical devices for the treatment of glaucoma, a cause of blindness. The Company is also engaged in the commercialization of its ophthalmic laser, 2RT. The Company’s segments include AlphaRET and Glaucoma surgical devices. The Company's AlphaRET segment has 2RT, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pause laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the design, manufacture, marketing and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. The Company's manufacturing facilities are located in Fremont, California, and Dunedin, New Zealand.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 11th, 1970
- Public Since
- October 12th, 1987
- No. of Shareholders
- 2,532
- No. of Employees
- 130
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 214,471,005
- Address
- 3-4 Second Avenue, ADELAIDE, 5095
- Web
- https://www.ellex.com/
- Phone
- +61 881045200
- Auditors
- PricewaterhouseCoopers
Upcoming Events for EYE
Similar to EYE
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Nova Eye Medical share price?
As of Today at 19:15 UTC, shares in Nova Eye Medical are trading at AU$0.25. This share price information is delayed by 15 minutes.
How has the Nova Eye Medical share price performed this year?
Shares in Nova Eye Medical last closed at AU$0.25 and the price had moved by -1.25% over the past 365 days. In terms of relative price strength the Nova Eye Medical share price has underperformed the ASX All Ordinaries Index by -5.54% over the past year.
What are the analyst and broker recommendations for Nova Eye Medical?
The overall consensus recommendation for Nova Eye Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nova Eye Medical dividend yield?
Nova Eye Medical does not currently pay a dividend.
Does Nova Eye Medical pay a dividend?
Nova Eye Medical does not currently pay a dividend.
When does Nova Eye Medical next pay dividends?
Nova Eye Medical does not currently pay a dividend.
How do I buy Nova Eye Medical shares?
To buy shares in Nova Eye Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nova Eye Medical?
As of the previous close price of AU$0.25, shares in Nova Eye Medical had a market capitalisation of AU$53.62m.
Where are Nova Eye Medical shares listed?
Here are the trading details for Nova Eye Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: EYE
What kind of share is Nova Eye Medical?
Based on an overall assessment of its quality, value and momentum Nova Eye Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nova Eye Medical share price forecast for 2024?
The analyst consensus target price for shares in Nova Eye Medical is AU$0.60. That is 140% above the last closing price of AU$0.25.
Analysts covering Nova Eye Medical currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.05 for the next financial year.
What is the trend in the Nova Eye Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nova Eye Medical. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +8.81%.
As of the last closing price of AU$0.25, shares in Nova Eye Medical were trading +16.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nova Eye Medical PE Ratio?
The Nova Eye Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nova Eye Medical?
Nova Eye Medical's management team is headed by:
- Victor Previn - CHM
- Mike Southard - EDR
- Simon Gray - SEC
- Tom Spurling - DRC
- Rahmon Coupe - NID